文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

同种异体培养角质形成细胞片移植治疗深二度烧伤创面的单中心、开放标签、随机、6个月、平行组研究:I/II期临床试验的原理与设计

A single-center, open-labeled, randomized, 6-month, parallel-group study to assess the safety and efficacy of allogeneic cultured keratinocyte sheet transplantation for deep second-degree burn wounds: rationale and design of phase I/II clinical trial.
PubMed 文献 · Trials · 2024-04-01

该研究设计为序贯开展的I期和II期临床试验,共纳入40例二度烧伤患者,评估同种异体角质形成细胞片移植的安全性和有效性。I期为非随机开放标签试验纳入5例患者,II期为随机开放标签试验纳入35例患者,在同一个患者的不同创面上比较同种异体皮肤移植联合自体皮肤移植与常规治疗(凡士林敷料和局部抗生素)的效果。移植后第3、7、10、14、21、28天随访,并在移植后第3个月和第6个月基于温哥华瘢痕量表和患者与观察者瘢痕评估量表进行创面闭合评估。

要点

  • I期非随机开放标签试验纳入5例患者,II期随机开放标签试验纳入35例患者,共40例二度烧伤患者接受同种异体角质形成细胞片移植。
  • II期在同一个患者的不同创面上比较同种异体皮肤移植联合自体皮肤移植与常规治疗(凡士林敷料和局部抗生素)。
  • 移植后第3、7、10、14、21、28天随访,第3个月和第6个月基于温哥华瘢痕量表和患者与观察者瘢痕评估量表评估创面闭合。

核心结论

  • 该研究将首次在伊朗解释基于细胞的皮肤替代物的设计与原理,并提出将该产品注册为该国烧伤创面管理的即用型产品。

研究设计与样本

  • 序贯开展两项临床试验:I期为非随机、开放标签试验,纳入5例患者;II期为随机、开放标签试验,纳入35例患者。
  • 共40例诊断为二度烧伤的患者将接受同种异体角质形成细胞片移植。
  • II期在同一个患者的不同创面上比较同种异体皮肤移植联合自体皮肤移植与常规治疗(包括凡士林敷料和局部抗生素)的安全性和有效性。
  • 移植后第3、7、10、14、21、28天随访;移植后第3个月和第6个月基于温哥华瘢痕量表和患者与观察者瘢痕评估量表进行创面闭合评估。
  • 试验注册:I期伊朗临床试验注册库(IRCT)IRCT20080728001031N31,注册日期2022年4月23日;II期IRCT20080728001031N36,注册日期2024年3月15日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Burn-related injuries are a major global health issue, causing 180,000 deaths per year. Early debridement of necrotic tissue in association with a split-thickness skin graft is usually administered for some of the 2nd- and 3rd-degree injuries. However, this approach can be complicated by factors such as a lack of proper donor sites. Artificial skin substitutes have attracted much attention for burn-related injuries. Keratinocyte sheets are one of the skin substitutes that their safety and efficacy have been reported by previous studies. METHODS: Two consecutive clinical trials were designed, one of them is phase I, a non-randomized, open-label trial with 5 patients, and phase II is a randomized and open-label trial with 35 patients. A total number of 40 patients diagnosed with 2nd-degree burn injury will receive allogenic keratinocyte sheet transplantation. The safety and efficacy of allogeneic skin graft with autograft skin transplantation and conventional treatments, including Vaseline dressing and topical antibiotic, will be compared in different wounds of a single patient in phase II. After the transplantation, patients will be followed up on days 3, 7, 10, 14, 21, and 28. In the 3rd and 6th months after the transplantation scar, a wound closure assessment will be conducted based on the Vancouver Scar Scale and the Patient and Observer Scar Assessment Scale. DISCUSSION: This study will explain the design and rationale of a cellular-based skin substitute for the first time in Iran. In addition, this work proposes this product being registered as an off-the-shelf product for burn wound management in the country. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT) IRCT20080728001031N31, 2022-04-23 for phase I and IRCT20080728001031N36, 2024-03-15 for phase II.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Farzanbakhsh S, Shahrbaf MA, Madani H, et al. A single-center, open-labeled, randomized, 6-month, parallel-group study to assess the safety and efficacy of allogeneic cultured keratinocyte sheet transplantation for deep second-degree burn wounds: rationale and design of phase I/II clinical trial. Trials. 2024. PMID: 38556879. doi:10.1186/s13063-024-08070-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。